News

As the push to contain clinical trial costs and make informed business decisions continues, more pharma and CROs are looking at internal and external benchmarking and metrics to evaluate their performance-both successes and challenges. This e-Book includes articles that show how analytics uncover problem areas in clinical operations, as well as metrics and databases that are used to pinpoint internal or external performance issues.

An article recently appeared in Applied Clinical Trials, which indicated that oncology trials are taking longer to complete, and the article suggested that the duration of oncology clinical trials in certain phases increased by one year to one and a half years.1 Moreover, the article delineates that ameliorations in trial duration were most likely a result of increasing protocol complexi

One of the worrisome aspects of the U.S. Open Payments transparency program is that it may discourage doctors from serving as investigators in clinical studies. The two-year-old program requires public disclosure of payments by drug and medical device manufacturers to health care professionals (HCPs) and teaching hospitals for conducting clinical trials, as well as for marketing and consulting activities. But an anomaly in the program credits to the principal investigator (PI) heading up a research site the full payment for managing and carrying out the study at that site.